GRO Biosciences
PrivateLast Round
Series B
Jul 19, 2024
Est. Valuation
$90.3M
Total Funding Raised
$88.4M
Company Overview
GRO Biosciences operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Series B round in July 2024.
GRO Biosciences is a biotechnology company that develops enhanced protein therapeutics using genomically recoded organisms to create biologics with non-standard amino acids for improved potency, stability, and targeted delivery.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
GRO Biosciences Comparables
Compare GRO Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Pearl Bio | 87% | |
| BrickBio, Inc. | 84% | |
| Tektonyx Bio, Inc. | 82% |
For institutional investors. Book with your work email.
GRO Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jul 19, 2024 | ||||
| Series A | Nov 3, 2021 | ||||
| Grant | Sep 15, 2020 | ||||
| Seed | Sep 28, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
GRO Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series B, Series A |
| Access Industries | Series B |
| Digitalis Ventures | Seed, Series A, Series B |
| Innovation Endeavors | Series A, Seed, Series B |
| Atlas Venture | Series B |
| Leaps by Bayer | Series B, Series A |
| Access Biotechnology | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 19, 2024
$60M round led by Access Biotechnology, Access Industries, and Atlas Venture.
- Nov 3, 2021
$25M round led by Leaps by Bayer and Redmile Group.
For institutional investors. Book with your work email.
GRO Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about GRO Biosciences's valuation, stock price, and market status.
Is GRO Biosciences a public or private company?
GRO Biosciences is a private company.
What is the current stock price of GRO Biosciences?
GRO Biosciences is a private company, so its shares have no public market price. Caplight tracks GRO Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is GRO Biosciences worth (valuation)?
GRO Biosciences's valuation is estimated at $90.3M based on funding round data.
Can I buy GRO Biosciences stock?
GRO Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was GRO Biosciences's last funding round?
GRO Biosciences's most recent funding round was Series B on July 19, 2024.
Who are the main investors in GRO Biosciences?
Key investors in GRO Biosciences include Redmile Group, Access Industries, Digitalis Ventures, Atlas Venture, Leaps by Bayer.
Will GRO Biosciences IPO soon?
No public IPO plans have been announced for GRO Biosciences.
How can I track GRO Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in GRO Biosciences's shares on secondary markets.